NCT02028442 - Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2012

Primary Completion Date

April 29, 2016

Study Completion Date

April 29, 2016

Conditions

Solid Tumours of Epithelial OriginMetastatic Colorectal CancerMetastatic Bladder Cancer

Interventions

BIOLOGICAL

Enadenotucirev

Oncolytic virus

Trial Locations (6)

Ghent University Hospital, Ghent

START - Hospital Universitario Madrid Sanchinarrio, Madrid

Hospital Universitario Virgen del Rocio (HUVR), Seville

GZA ziekenhuizen campus Sint-Augustinus, Wilrijk

Cliniques Universitaires St Luc, Brussels

Institut Catala d Oncologica, Barcelona